Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (371-380 of 595) with videos related to

Pageof 60
Sort By:
Revue Medicale De Liege|November 3, 2012
[Influence of body weight on the natural history of and the therapeutic approaches to type 1 diabetes]M Franck, N Paquot, A J Scheen
Revue Medicale De Liege|November 21, 2002
[Smoking, insulin resistance and type 2 diabetes]D Magis, I Geronooz, A J Scheen
Revue Medicale De Liege|August 28, 2003
[Prevention of diabetic nephropathy: from microalbuminuria to end-stage renal insufficiency]L Weekers, A J Scheen, G Rorive
Revue Medicale De Liege|November 5, 2013
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Revue Medicale De Liege|February 5, 2021
[Anticoagulation of diabetic patients with nonvalvular atrial fibrillation]A J Scheen, M Sprynger, P Lancellotti
Acta Clinica Belgica|June 24, 2015
Inflammatory markers and cardiometabolic diseasesN Esser, N Paquot, A J Scheen
Revue Medicale De Liege|December 22, 1999
[Arterial hypertension and type 2 diabetes]A J Scheen, F Estrella, L Weekers
Revue Medicale De Liege|September 23, 2010
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Revue Medicale De Liege|April 10, 2012
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]A J Scheen, L F Van Gaal
Revue Medicale Suisse|September 24, 2009
[Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics]A Nyssen, V Legrand, A J Scheen
Pageof 60

Showing results (371-380 of 595) with videos related to

Sort By:
Pageof 60
Revue Medicale De Liege|November 3, 2012
[Influence of body weight on the natural history of and the therapeutic approaches to type 1 diabetes]M Franck, N Paquot, A J Scheen
Revue Medicale De Liege|November 21, 2002
[Smoking, insulin resistance and type 2 diabetes]D Magis, I Geronooz, A J Scheen
Revue Medicale De Liege|August 28, 2003
[Prevention of diabetic nephropathy: from microalbuminuria to end-stage renal insufficiency]L Weekers, A J Scheen, G Rorive
Revue Medicale De Liege|November 5, 2013
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Revue Medicale De Liege|February 5, 2021
[Anticoagulation of diabetic patients with nonvalvular atrial fibrillation]A J Scheen, M Sprynger, P Lancellotti
Acta Clinica Belgica|June 24, 2015
Inflammatory markers and cardiometabolic diseasesN Esser, N Paquot, A J Scheen
Revue Medicale De Liege|December 22, 1999
[Arterial hypertension and type 2 diabetes]A J Scheen, F Estrella, L Weekers
Revue Medicale De Liege|September 23, 2010
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Revue Medicale De Liege|April 10, 2012
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]A J Scheen, L F Van Gaal
Revue Medicale Suisse|September 24, 2009
[Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics]A Nyssen, V Legrand, A J Scheen
Pageof 60